Exact Sciences Corporation (EXAS): Price and Financial Metrics

Exact Sciences Corporation (EXAS): $32.49

-0.68 (-2.05%)

POWR Rating

Component Grades














  • Growth is the dimension where EXAS ranks best; there it ranks ahead of 86.65% of US stocks.
  • EXAS's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • EXAS ranks lowest in Momentum; there it ranks in the 4th percentile.

EXAS Stock Summary

  • EXACT SCIENCES CORP's market capitalization of $5,722,871,621 is ahead of 78.95% of US-listed equities.
  • In terms of twelve month growth in earnings before interest and taxes, EXACT SCIENCES CORP is reporting a growth rate of -30.81%; that's higher than 30.06% of US stocks.
  • In terms of volatility of its share price, EXAS is more volatile than 78.55% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to EXACT SCIENCES CORP, a group of peers worth examining would be VCYT, VSAT, APEN, OSIS, and MAPS.
  • Visit EXAS's SEC page to see the company's official filings. To visit the company's web site, go to www.exactsciences.com.

EXAS Valuation Summary

  • EXAS's EV/EBIT ratio is -11.2; this is 240% lower than that of the median Healthcare stock.
  • Over the past 243 months, EXAS's price/earnings ratio has gone up 1.1.

Below are key valuation metrics over time for EXAS.

Stock Date P/S P/B P/E EV/EBIT
EXAS 2022-09-23 3.1 1.8 -8.0 -11.2
EXAS 2022-09-22 3.1 1.9 -8.3 -11.4
EXAS 2022-09-21 3.3 2.0 -8.7 -11.9
EXAS 2022-09-20 3.5 2.1 -9.1 -12.3
EXAS 2022-09-19 3.5 2.1 -9.2 -12.4
EXAS 2022-09-16 3.6 2.2 -9.5 -12.6

EXAS Growth Metrics

    Its 5 year price growth rate is now at 365.63%.
  • The 4 year price growth rate now stands at 365.63%.
  • The 5 year net income to common stockholders growth rate now stands at 37.29%.
EXAS's revenue has moved up $1,630,480,000 over the prior 52 months.

The table below shows EXAS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 1,938.402 -300.016 -734.549
2022-03-31 1,851.581 -198.763 -745.398
2021-12-31 1,767.087 -102.236 -595.625
2021-09-30 1,759.614 33.74 -811.824
2021-06-30 1,711.598 156.289 -864.77
2021-03-31 1,545.647 109.082 -774

EXAS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EXAS has a Quality Grade of D, ranking ahead of 24.25% of graded US stocks.
  • EXAS's asset turnover comes in at 0.281 -- ranking 445th of 561 Business Services stocks.
  • ISGN, ADBE, and FTAI are the stocks whose asset turnover ratios are most correlated with EXAS.

The table below shows EXAS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.281 0.750 -0.310
2021-06-30 0.301 0.755 -0.344
2021-03-31 0.302 0.752 -0.332
2020-12-31 0.328 0.762 -0.274
2020-09-30 0.315 0.755 -0.171
2020-06-30 0.319 0.751 -0.126

EXAS Price Target

For more insight on analysts targets of EXAS, see our EXAS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $148.88 Average Broker Recommendation 1.28 (Strong Buy)

EXAS Stock Price Chart Interactive Chart >

Price chart for EXAS

EXAS Price/Volume Stats

Current price $32.49 52-week high $104.50
Prev. close $33.17 52-week low $31.62
Day low $32.46 Volume 2,301,100
Day high $34.51 Avg. volume 2,160,568
50-day MA $39.96 Dividend yield N/A
200-day MA $57.09 Market Cap 5.75B

Exact Sciences Corporation (EXAS) Company Bio

Exact Sciences is a molecular diagnostics company focused on gastrointestinal cancers. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. The company was founded in 1995 and is based in Madison, Wisconsin.

EXAS Latest News Stream

Event/Time News Detail
Loading, please wait...

EXAS Latest Social Stream

Loading social stream, please wait...

View Full EXAS Social Stream

Latest EXAS News From Around the Web

Below are the latest news stories about EXACT SCIENCES CORP that investors may wish to consider to help them evaluate EXAS as an investment opportunity.

3 Growth Stocks That Could Double Your Money, According to Wall Street

With inflation, rising interest rates, and fear of a recession weighing on investors' minds, even the best stocks have been in freefall. Investment bank analysts on Wall Street have identified a handful of top growth stocks that have a lot more potential than their present market values would suggest. Wall Street analysts who follow Exact Sciences think its best days are still to come.

Yahoo | September 29, 2022

YmAbs Therapeutics, Inc. (YMAB) Soars 5.2%: Is Further Upside Left in the Stock?

YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Yahoo | September 29, 2022

Here's Why Investors Should Hold Exact Sciences (EXAS) Stock

Growth in Exact Sciences' (EXAS) legacy Screening business is attributable to Cologuard volume growth and contributions from the PreventionGenetics, Biomatrica and Oncoguard Liver products.

Yahoo | September 28, 2022

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Yahoo | September 27, 2022

7 Nasdaq Stocks to Buy on the Dip or You’ll Be Kicking Yourself Later

Investors should consider buying these Nasdaq stocks on the dip while they still can before the market reverses higher.

Larry Ramer on InvestorPlace | September 21, 2022

Read More 'EXAS' Stories Here

EXAS Price Returns

1-mo -10.35%
3-mo -21.01%
6-mo -57.38%
1-year -66.21%
3-year -62.85%
5-year -32.23%
YTD -58.26%
2021 -41.26%
2020 43.26%
2019 46.56%
2018 20.10%
2017 293.26%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5875 seconds.